Delving into the Latest Updates on Phrontline Biopharma (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Urogenital Diseases

Dual payload Antibody drug conjugate (Dual payload ADC)

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Dual payload Antibody drug conjugate (Dual payload ADC)	5
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

EGFR x HER3 x Top I x Tubulin	1
Top I x Trop-2 x Tubulin x nectin-4	1
EGFR x Top I x Tubulin x c-Met	1
HER2 x Top I x Tubulin	1
CD276 x EGFR x Top I	1

剂量递增研究（Ia）主要研究目的： 1.评估注射用TJ101在晚期实体瘤受试者中的安全性和耐受性。剂量扩展研究（Ib）主要研究目的： 1.评估注射用TJ101在RDEs剂量下在晚期实体瘤受试者中的安全性、耐受性和初步抗肿瘤活性。 2.确定注射用TJ101在晚期实体瘤受试者中的II期临床研究推荐剂量（RP2D）。

[Translation]

Dose-Escalation Study (Ia) Primary Study Objectives: 1. Evaluate the safety and tolerability of TJ101 for injection in subjects with advanced solid tumors. Dose-Expansion Study (Ib) Primary Study Objectives: 1. Evaluate the safety, tolerability, and preliminary anti-tumor activity of TJ101 for injection at the recommended dose (RDE) in subjects with advanced solid tumors. 2. Determine the recommended dose (RP2D) for the Phase II clinical study of TJ101 for injection in subjects with advanced solid tumors.

Start Date-

Sponsor / Collaborator

Yi Xian Yi Yao （ Hang Zhou ） You Xian Gong Si

100 Clinical Results associated with Phrontline Biopharma (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Phrontline Biopharma (Suzhou) Co., Ltd.

Login to view more data

100 Deals associated with Phrontline Biopharma (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Phrontline Biopharma (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

5

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TJ-101 (Phrontline) ( CD276 x EGFR x Top I )	Advanced Malignant Solid Neoplasm More	Phase 1
TJ-102 (Phrontline) ( CDH6 x FOLR1 x Top I x Tubulin )	Ovarian Epithelial Carcinoma More	Preclinical
TJ-111 ( Top I x Trop-2 x Tubulin x nectin-4 )	Urethral Neoplasms More	Preclinical
TJ-108 ( EGFR x Top I x Tubulin x c-Met )	Non-Small Cell Lung Cancer More	Preclinical
TJ-106 ( HER2 x Top I x Tubulin )	Breast Cancer More	Preclinical